Seminars in Oncology
Volume 33, Issue 6 , Pages 631-641 , December 2006

Steroid Receptors and Their Role in the Biology and Control of Breast Cancer Growth

  • Fernando Cordera
    • ,
  • V. Craig Jordan

      Affiliations

    • Corresponding Author InformationAddress correspondence to V. Craig Jordan, OBE, PhD, DSc, Vice President and Scientific Director for Medical Science, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111-2497.

References 

  1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet. 1896;2:104–107
  2. Hwang ES, Chew T, Shiboski S, et al. Risk factors for estrogen receptor-positive breast cancer. Arch Surg. 2005;140:58–62
  3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  4. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344:276–285
  5. Russo J, Russo IH. Genotoxicity of steroidal estrogens. Trends Endocrinol Metab. 2004;15:211–214
  6. Helguero LA, Faulds MH, Gustafsson JA, et al. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene. 2005;24:6605–6616
  7. Khan S, Rogers M, Obando J, et al. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res. 1994;54:993–997
  8. Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat. 2002;74:199–211
  9. Lawson J, Field A, Champion S, et al. Low oestrogen receptor alfa; expression in normal breast tissue underlies low breast cancer incidence in Japan. Lancet. 1999;354:1787–1788
  10. Jensen EV, Jordan VC. The estrogen receptor: A model for molecular medicine. Clin Cancer Res. 2003;9:1980–1989
  11. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–1717
  12. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254–1261
  13. Anderson WF, Chu KC, Chatterjee N, et al. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology, and End Results database. J Clin Oncol. 2001;19:18–27
  14. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–1618
  15. Jordan VC. Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–213
  16. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol. 2003;23:7512–7517
  17. Hull D3d, Clark G, Osborne C, et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983;43:413–416
  18. Gross G, Clark G, Chamness G, et al. Multiple progesterone receptor assays in human breast cancer. Cancer Res. 1984;44:836–840
  19. Balleiner RL, Earl MJ, Greenberg ML, et al. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer. 1999;79:1564–1571
  20. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996;93:5925–5930
  21. Mosselman S, Polman J, Dijkema R. ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392:49–53
  22. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res. 2004;10:3621–3628
  23. Chen JQ, Delannoy M, Cooke C, et al. Mitochondrial localization of ER{alpha} and ER{beta} in human MCF7 cells. Am J Physiol Endocrinol Metab. 2004;286:E1011–E1022
  24. Levin ER. Cellular functions of plasma membrane estrogen receptors. Steroids. 2002;67:471–475
  25. Faulds MH, Olsen H, Helguero LA, et al. Estrogen receptor functional activity changes during differentiation of mammary epithelial cells. Mol Endocrinol. 2004;18:412–421
  26. Koehler KF, Helguero LA, Haldosen L-A, et al. Reflections on the discovery and significance of estrogen receptor {beta}. Endocr Rev. 2005;26:465–478
  27. Fuqua SA, Schiff R, Parra I, et al. Estrogen receptor beta protein in human breast cancer: Correlation with clinical tumor parameters. Cancer Res. 2003;63:2434–9243
  28. Yang S-H, Liu R, Perez EJ, et al. Mitochondrial localization of estrogen receptor {beta}. Proc Natl Acad Sci U S A. 2004;101:4130–4135
  29. Bocchinfuso WP, Lindzey JK, Hewitt SC, et al. Induction of mammary gland development in estrogen receptor-{alpha} knockout mice. Endocrinology. 2000;141:2982–2994
  30. Forster C, Makela S, Warri A, et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A. 2002;99:15578–15583
  31. Skliris GP, Parkes AT, Limer JL, et al. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, Western blotting, and flow cytometry in human breast tissue. J Pathol. 2002;197:155–162
  32. Speirs V, Parkes AT, Kerin MJ, et al. Coexpression of estrogen receptor {{alpha}} and {beta}: Poor prognostic factors in human breast cancer?. Cancer Res. 1999;59:525–528
  33. Speirs V, Malone C, Walton DS, et al. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999;59:5421–5424
  34. Dotzlaw H, Leygue E, Watson PH, et al. Estrogen receptor-[β] messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res. 1999;59:529–532
  35. Iwao K, Miyoshi Y, Egawa C, et al. Quantitative analysis of estrogen receptor-[β] mRNA and its variants in human breast cancers. Int J Cancer. 2000;88:733–736
  36. Knowlden JM, Gee JMW, Robertson JFR, et al. A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. Int J Cancer. 2000;86:209–212
  37. Shaw JA, Udokang K, Mosquera JM, et al. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J Pathol. 2002;198:450–457
  38. Cullen R, Maguire TM, McDermott EW, et al. Studies on oestrogen receptor-[α] and -[β] mRNA in breast cancer. Eur J Cancer. 2001;37:1118–1122
  39. De Cremoux P, Tran-Perennou C, Elie C, et al. Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction: Correlation with protein assays. Biochem Pharmacol. 2002;64:507–515
  40. Bieche I, Parfait B, Laurendeau I, et al. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene. 2001;20:8109–8115
  41. Park BW, Kim KS, Heo MK, et al. Expression of estrogen receptor-beta in normal mammary and tumor tissues: Is it protective in breast carcinogenesis?. Breast Cancer Res Treat. 2003;80:79–85
  42. Jarvinen TAH, Pelto-Huikko M, Holli K, et al. Estrogen receptor [β] is coexpressed with ER[α] and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 2000;156:29–35
  43. Omoto Y, Kobayashi S, Inoue S, et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer. 2002;38:380–386
  44. Mann S, Laucirica R, Carlson N, et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol. 2001;32:113–118
  45. Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor [β] protein in proliferative preinvasive mammary tumors. Cancer Res. 2001;61:2537–2541
  46. Iwase H, Zhang Z, Omoto Y, et al. Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer. Cancer Chemother Pharmacol. 2003;52(suppl):S34-S8
  47. Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ER[β]) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer. 2003;39:1251–1258
  48. Horvath LG, Henshall SM, Lee CS, et al. Frequent loss of estrogen receptor-{beta} expression in prostate cancer. Cancer Res. 2001;61:5331–5335
  49. Skliris GP, Parkes J, Limer JL, et al. Evaluation of seven oestrogen receptor? (antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue). J Pathol. 2002;197:155–162
  50. McInerney EM, Weis KE, Sun J, et al. Transcription activation by the human estrogen receptor subtype {beta} (ER{beta}) studied with ER{beta} and ER{alpha} receptor chimeras. Endocrinology. 1998;139:4513–4522
  51. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999;140:5566–5578
  52. Duong V, Licznar A, Margueron R, et al. ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene. 2005;9:1–8
  53. Leong H, Sloan JR, Nash PD, et al. Recruitment of Histone Deacetylase 4 to the N-terminal region of estrogen receptor {alpha}. Mol Endocrinol. 2005;19:2930–2942
  54. Jang ER, Lim SJ, Lee ES, et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene. 2004;23:1724–1736
  55. Pandolfi PP. Transcription therapy for cancer. Oncogene. 2001;20:3116–3127
  56. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer. 2001;1:194–202
  57. Margueron R, Duong V, Bonnet S, et al. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. J Mol Endocrinol. 2004;32:583–594
  58. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab. 2001;12:294–300
  59. Osborne CK, Schiff R. Estrogen-receptor biology: Continuing progress and therapeutic implications. J Clin Oncol. 2005;23:1616–1622
  60. McKenna NJ, Lanz RB, O’Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev. 1999;20:321–344
  61. Wang Z, Rose DW, Hermanson O, et al. Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci U S A. 2000;97:13549–13554
  62. List H-J, Lauritsen KJ, Reiter R, et al. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem. 2001;276:23763–23768
  63. Torres-Arzayus MI, de Mora JF, Yuan J, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell. 2004;6:263–274
  64. Kuang S-Q, Liao L, Zhang H, et al. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res. 2004;64:1875–1885
  65. Labhart P, Karmakar S, Salicru EM, et al. Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. Proc Natl Acad Sci U S A. 2005;102:1339–1344
  66. Lavinsky RM, Jepsen K, Heinzel T, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998;95:2920–2925
  67. Simon SLR, Parkes A, Leygue E, et al. Expression of a repressor of estrogen receptor activity in human breast tumors: Relationship to some known prognostic markers. Cancer Res. 2000;60:2796–2799
  68. Steffi O. Scaffold attachment factors SAFB1 and SAFB2: Innocent bystanders or critical players in breast tumorigenesis?. J Cell Biochem. 2003;90:653–661
  69. Zheng L, Annab LA, Afshari CA, et al. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A. 2001;98:9587–9592
  70. Huang G, Song Y, He G. [mRNA expression and mutation of MTA1 and nm23H1 genes in ovarian carcinoma in relation to lymph node metastasis]. Zhonghua Zhong Liu Za Zhi. 2001;23:31–34
  71. Schiff R, Reddy P, Ahotupa M, et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000;92:1926–1934
  72. Keen JC, Davidson NE. The biology of breast carcinoma. Cancer. 2003;97(suppl):825–833
  73. Graham JD, Roman SD, McGowan E, et al. Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells. J Biol Chem. 1995;270:30693–30700
  74. Yang X, Phillips DL, Ferguson AT, et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001;61:7025–7029
  75. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–3167
  76. Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65:11118–11128
  77. Matsui Y, Halter SA, Holt JT, et al. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell. 1990;61:1147–1155
  78. Zhu L, Chow LWC, Loo WTY, et al. Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial. Clin Cancer Res. 2004;10:4639–4644
  79. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003;95:353–361
  80. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290–297
  81. Cormier E, Wolf M, Jordan V. Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res. 1989;49:576–580
  82. Cormier EM, Jordan VC. Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. Eur J Cancer Clin Oncol. 1989;25:57–63
  83. Robinson SP, Jordan V. The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: Possible role of antiestrogen failure. Eur J Cancer Clin Oncol. 1989;25:493–497
  84. Robinson SP, Jordan VC. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res. 1989;49:1758–1762
  85. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–1388
  86. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAMA. 1999;281:2189–2197
  87. Miller WR. Aromatase inhibitors: Mechanism of action and role in the treatment of breast cancer. Semin Oncol. 2003;30(suppl 14):3–11
  88. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271
  89. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092
  90. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23:5138–5147
  91. ATAC Trialists’ Group. L Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  92. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867–3873
  93. Dauvois S, White R, Parker M. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993;106:1377–1388
  94. Carlson RW. The history and mechanism of action of fulvestrant. Clin Breast Cancer. 2005;6(suppl 1):5–8
  95. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605–1613
  96. Bross PF, Cohen MH, Williams GA, et al. FDA drug approval summaries: Fulvestrant. Oncologist. 2002;7:477–480
  97. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96:926–935
  98. Stewart HJ, Forrest AP, Everington D, et al. The Scottish Cancer Trials Breast Group Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br J Cancer. 1996;74:297–299
  99. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–690
  100. Fuqua SAW, Schiff RT. The biology of estrogen receptors. In:  Harris JR,  Lippman ME,  Morrow M, et al. editor. (eds): Diseases of the Breast (ed 3). Philadelphia, PA: Lippincott Williams & Wilkins; 2004;p. 585–602
  101. Berstein LM, Wang JP, Zheng H, et al. Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clin Cancer Res. 2004;10:1530–1534
  102. Yao K, Bentrem DJ, England G, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000;6:2028–2036
  103. Liu H, Lee E-S, Gajdos C, et al. Apoptotic action of 17{beta}-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst. 2003;95:1586–1597
  104. Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005;97:1746–1759
  105. Osipo C, Gajdos C, Liu H, et al. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst. 2003;95:1597–1608
  106. Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001;67:111–116

 Supported in part by the Specialized Program of Research Excellence in Breast Cancer P50CA89018 (V.C.J.), the Weg Fund at the Fox Chase Cancer Center, and the Avon Foundation.

PII: S0093-7754(06)00331-9

doi: 10.1053/j.seminoncol.2006.08.020

Seminars in Oncology
Volume 33, Issue 6 , Pages 631-641 , December 2006

Article Tools

* Image Usage & Resolution